Showing results (81-90 of 135) with videos related to

Sort By:
Pageof 14
Liver Cancer|August 11, 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver CancersJames J Harding, Ahmad Awada, Gael Roth, et al.
Neurophysiologie Clinique = Clinical Neurophysiology|May 23, 2018
Recommendations for the use of electroencephalography and evoked potentials in comatose patientsNathalie André-Obadia, Julie Zyss, Martine Gavaret, et al.
Journal of Hepatology|April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trialRichard S Finn, Philippe Merle, Alessandro Granito, et al.
Radiology|May 1, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II TrialBoris Guiu, Patrick Chevallier, Eric Assenat, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2025
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY DataHéloïse Bourien, Xavier Adhoute, Boris Campillo-Gimenez, et al.
Hepatology International|May 30, 2019
Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcomeHualin Wang, Bouchra Lekbaby, Nadim Fares, et al.
ESMO Open|November 7, 2017
Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinomaPhilippe Merle, Philippe Camus, Armand Abergel, et al.
Therapeutic Advances in Medical Oncology|October 7, 2021
ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240Arndt Vogel, Philippe Merle, Chris Verslype, et al.
Liver Cancer|February 28, 2022
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular CarcinomaLorenza Rimassa, Robin Kate Kelley, Tim Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2020
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular CarcinomaRobin Kate Kelley, Tim Meyer, Lorenza Rimassa, et al.
Pageof 14